SHEBA MEDICAL CENTER

NAYA Biosciences plans to start a clinical trial in early 2025 at leading Israeli medical centers to evaluate NY-303, a GPC3-targeting NK Engager bispecific antibody for hepatocellular carcinoma in non-responders to first-line immunotherapy.

NAYA Biosciences announces plans to initiate a clinical trial for NY-303, a GPC3-targeting NK Engager bispecific antibody for hepatocellular carcinoma, following regulatory approvals in Israel. The trial aims to evaluate safety and efficacy in patients not responding to first-line immunotherapy, with Phase 1 starting in early 2025 in Israel and Phase 2a potentially expanding to the US and Europe.

The FDA approved a novel antipsychotic schizophrenia drug, Cobenfy, targeting cholinergic receptors to reduce side effects like weight gain and cognitive impairment. Cobenfy's monthly cost is $1,850, marking a market-driven win over government-funded research, which has yet to significantly benefit patients.

Israel’s health care and biotech leaders showcased AI, personalized medicine, and clinical trial advancements at the ARC Summit 2024, despite ongoing conflict. Announcements included the launch of embARC Ventures, a health-tech startup accelerator, and a partnership with Paradigm Health Inc. for a global clinical trials network. The summit highlighted Israel’s resilience in health care innovation, emphasizing AI’s role in transforming patient care and operational efficiency.

Sheba Medical Center and ARC Innovation partner with Paradigm Health to establish a global clinical research network, aiming to revolutionize trials through AI-driven automation, enhancing accessibility, efficiency, and patient-centeredness.